Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration

By afschroeder • December 9, 2025

Rosen LS, Ottensmeier C, Hawkins M, Naing A, Sonpavde G, Van Tine BA, Parkes EE, O'Cathail SM, Ji RR, Thomas M, Stacey A, Sasso MS, Rosen O. Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV Administration. J Immunother Precis Oncol. 2025 Nov 25;8(4):263-275. doi: 10.36401/JIPO-25-18. PMID: 41358276; PMCID: PMC12681188.

Tags: Hematology/Oncology, immunotherapy, oncolytic immunotherapies, Publications, solid tumors, Tolerability, viral persistence

Related Posts

Results from a Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors

Ganz PA, Van Dyk K, Crespi CM, Petersen L, Sedrak MS, Bower JE. Results from a Phase II Single Arm Trial Evaluating the Safety and[...]

Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study

McKean M, Chmielowski B, Butler MO, Carvajal RD, Rodon J, Carlino MS, Kim KB, Wise-Draper TM, Khan S, Salama AKS, Moser J, Ang A, Barrios[...]

Conversational artificial intelligence for geriatric screening: A mixed-methods feasibility study

Naeim A, Cheng J, Spiegel B, Bakshian A, Tetrault E, Mehra M, Amini D, Krut Z, Shang H, Sedrak MS, Bui A, Johnson T, Wang[...]